Source: Υπουργείο Υγείας (CY) Revision Year: 2019 Publisher: MEDOCHEMIE LTD, 1-10 Constantinoupoleos street, 3011 Limassol, Cyprus
Selegos 5 mg tablets.
| Pharmaceutical Form |
|---|
|
Tablet. Round, white, flat, scored tablets with 7mm diameter. |
Each tablet contains 5mg of Selegiline hydrochloride.
Excipient with known effect: lactose monohydrate. Each 5 mg tablet contains 85 mg lactose monohydrate.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Selegiline |
Selegiline is a selective MAO-B-inhibitor which prevents dopamine breakdown in the brain. It also inhibits the reuptake of dopamine at the presynaptic dopamine receptor. These effects potentiate dopaminergic function in the brain and help to even out and prolong the effect of exogenous and endogenous dopamine. Thus, selegiline potentiates and prolongs the effect of levodopa in the treatment of parkinsonism. |
| List of Excipients |
|---|
|
Selegos 5 mg tablets also contain lactose monohydrate, povidone, maize starch, talc and magnesium stearate. |
Selegos tablets are packed in the following: PVC/PCTFE film-aluminium foil blisters of ten tablets, in packs of 10, 50, 100, 500 and 1000 tablets.
Dispensing packs of either screw cap or securitainer type made of polyvinylchloride (PVC) containing 100, 500 or 1000 tablets.
Not all pack sizes may be marketed.
MEDOCHEMIE LTD, 1-10 Constantinoupoleos street, 3011 Limassol, Cyprus
14025
Date of First Authorization: 26/11/1992
Date of Renewal: 20/03/2009
| Drug | Countries | |
|---|---|---|
| SELEGOS | Cyprus, Hong Kong, Romania, Singapore |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
